BioLife Solutions (BLFS) Receives News Sentiment Rating of 0.23

News headlines about BioLife Solutions (NASDAQ:BLFS) have been trending somewhat positive this week, Accern Sentiment reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. BioLife Solutions earned a news impact score of 0.23 on Accern’s scale. Accern also gave news stories about the medical equipment provider an impact score of 44.6648945672611 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Several brokerages have recently weighed in on BLFS. Maxim Group set a $6.00 price target on BioLife Solutions and gave the company a “buy” rating in a research note on Friday, August 11th. Janney Montgomery Scott raised BioLife Solutions from a “neutral” rating to a “buy” rating and increased their price target for the company from $2.62 to $5.00 in a research note on Wednesday, July 5th.

Shares of BioLife Solutions (NASDAQ BLFS) traded down 5.23% during midday trading on Friday, hitting $4.35. The stock had a trading volume of 168,018 shares. The stock’s market cap is $57.54 million. BioLife Solutions has a 1-year low of $1.43 and a 1-year high of $4.70. The firm’s 50-day moving average price is $3.44 and its 200-day moving average price is $2.44.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings results on Thursday, August 10th. The medical equipment provider reported ($0.06) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.06). BioLife Solutions had a negative net margin of 63.71% and a negative return on equity of 64.98%. The firm had revenue of $2.56 million during the quarter, compared to the consensus estimate of $2.40 million. Analysts forecast that BioLife Solutions will post ($0.24) earnings per share for the current year.

WARNING: This story was originally published by BNB Daily and is owned by of BNB Daily. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.baseball-news-blog.com/2017/08/19/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-biolife-solutions-blfs-stock-price-updated.html.

BioLife Solutions Company Profile

BioLife Solutions, Inc (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers.

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply